Literature DB >> 30807447

Diagnostic accuracy of γ-glutamyl transpeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: a meta-analysis.

Ming-Jian Lian1, Jia-Qin Zhang1, Shi-Dong Chen1, Dong-Dong Zhang1, Yuan-Yuan Yang1, Guo-Lin Hong1,2.   

Abstract

BACKGROUND AND AIM: Emerging published data on the accuracy of γ-glutamyl transpeptidase-to-platelet ratio (GPR) for diagnosing hepatitis B virus (HBV)-related fibrosis are inconsistent. The aim of this study was to systematically review the performance of GPR for diagnosing HBV-related significant fibrosis, severe fibrosis, and cirrhosis. PATIENTS AND METHODS: A comprehensive literature search of PubMed, Web of Science, and EMBASE was conducted before July 2018. Study selection was performed according to inclusion and exclusion criteria. The relevant parameters of eligible studies were abstracted. The methodological quality was assessed according to the Quality Assessment of Diagnostic Accuracy Studies. Areas under summary receiver operating characteristic curves, sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratios were used to examine the GPR accuracy for the diagnosis of significant fibrosis, severe fibrosis, and cirrhosis.
RESULTS: A total of 10 studies including 5882 patients with HBV infection underwent liver biopsy were incorporated. The prevalence of significant fibrosis, severe fibrosis, and cirrhosis were 58% (range: 22-72%), 36% (range: 10-55%), and 19% (range: 2-33%), respectively. Areas under summary receiver operating characteristic curves of GPR for predicting significant fibrosis, severe fibrosis, and cirrhosis were 0.733, 0.777, and 0.796, respectively. Subgroup analysis was performed according to geographical region and histological scoring system with similar results.
CONCLUSION: GPR has moderate diagnostic accuracy for predicting HBV-related significant fibrosis, severe fibrosis, and cirrhosis, and further studies with large sample size, rigorous design, multicenter study population are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30807447     DOI: 10.1097/MEG.0000000000001381

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study.

Authors:  Yun-Feng Zhu; Yi-Fei Tan; Xi Xu; Jin-Li Zheng; Bo-Han Zhang; Huai-Rong Tang; Jia-Yin Yang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

2.  Effect of Entecavir Combined with Adefovir Dipivoxil on Clinical Efficacy and TNF-α and IL-6 Levels in Patients with Hepatitis B Cirrhosis.

Authors:  Yonghuan Yu; Xinfeng Cui; Jingjing Zhao; Ting Jia; Baofeng Ren; Xiaoyan Zhang
Journal:  J Oncol       Date:  2021-08-24       Impact factor: 4.375

3.  Diagnostic Performance of Acoustic Radiation Force Impulse Imaging in Evaluating Liver Fibrosis in Patients with Chronic Hepatitis B Infection: A Cross-Sectional Study.

Authors:  Hoang Huu Bui; Van Huy Vo; Chuong Dinh Nguyen; Sang The Phan; Phong Tien Quach; Dung Bich Nguyen
Journal:  Indian J Radiol Imaging       Date:  2022-08-30

Review 4.  Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases.

Authors:  JianPing Wu; WeiLin Mao
Journal:  Dis Markers       Date:  2020-07-21       Impact factor: 3.434

5.  Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels.

Authors:  Lingmei Wang; Jiao Li; Kai Yang; Hao Zhang; Qin Wang; Xiongwen Lv; Shihe Guan
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

6.  Predictive performance of eLIFT for liver inflammation and fibrosis in chronic liver diseases.

Authors:  Zongguo Yang; Xin Ma; Xinlan Zhou; Dan Huang; Yanbing Wang; Xiufen Li; Wei Lu; Zhanqing Zhang; Rongrong Ding
Journal:  Int J Med Sci       Date:  2021-08-27       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.